Karyopharm
KPTI
Karyopharm (KPTI) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$2.32
- EPS estimate
- −$1.37
- EPS surprise
- −69.13%
- Revenue surprise
- +3.85%
- Revenue
- $33.4M
- Revenue estimate
- $32.2M
- Reported
- Aug 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | −$1.37 | −$2.32 | −69.13% | $33.4M | SEC |
| Q1 2026 | May 14, 2026 | −$1.42 | −$1.24 | +12.50% | $35.1M | SEC |
| Q4 2025 | Feb 12, 2026 | −$1.99 | −$5.71 | −186.32% | $34.1M | SEC |
| Q3 2025 | Nov 3, 2025 | −$3.47 | −$3.82 | −10.23% | $44.0M | SEC |
| Q2 2025 | Aug 11, 2025 | −$4.08 | −$4.32 | −5.84% | $37.9M | SEC |
| Q1 2025 | May 12, 2025 | −$4.42 | −$2.77 | +37.32% | $30.0M | SEC |
| Q4 2024 | Feb 19, 2025 | −$3.92 | −$3.60 | +8.20% | $30.5M | SEC |
| Q3 2024 | Nov 5, 2024 | −$3.94 | −$3.90 | +1.09% | $38.8M | SEC |
| Q2 2024 | Aug 6, 2024 | −$4.47 | −$3.00 | +32.85% | $42.8M | SEC |
| Q1 2024 | May 8, 2024 | −$5.01 | −$4.80 | +4.15% | $33.1M | SEC |
| Q4 2023 | Feb 29, 2024 | −$4.65 | −$5.40 | −16.13% | $33.7M | SEC |
| Q3 2023 | Nov 2, 2023 | −$4.20 | −$4.50 | −7.14% | $36.0M | SEC |
| Q2 2023 | Aug 2, 2023 | −$5.13 | −$4.35 | +15.26% | $37.6M | SEC |
| Q1 2023 | May 4, 2023 | −$5.51 | −$4.50 | +18.36% | $38.7M | SEC |
| Q4 2022 | Feb 15, 2023 | −$5.30 | −$6.45 | −21.81% | $33.6M | SEC |
| Q3 2022 | Nov 3, 2022 | −$8.48 | −$6.75 | +20.43% | $36.1M | SEC |
| Q2 2022 | Aug 4, 2022 | −$9.50 | −$9.30 | +2.11% | $39.7M | SEC |
| Q1 2022 | May 5, 2022 | −$9.47 | −$7.95 | +16.01% | $47.7M | SEC |
| Q4 2021 | Feb 8, 2022 | −$6.79 | $6.90 | +201.66% | $126.3M | SEC |
| Q3 2021 | Nov 3, 2021 | −$10.10 | −$10.35 | −2.48% | $37.7M | SEC |
Quarterly revenue
Frequently asked questions
When did Karyopharm (KPTI) last report earnings?
Karyopharm last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did KPTI beat earnings estimates?
No. Karyopharm reported EPS of −$2.32 for Q2 2026 against a −$1.37 estimate — a 69.13% miss.
How much revenue did KPTI report last quarter?
Karyopharm reported $33.4M in revenue for Q2 2026, against a consensus estimate of $32.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.